CCM
TARS icon

Cinctive Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Cinctive Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Sell
46,182
-22,587
-33% -$1.44M 0.11% 237
2026
Q1 		$4.82M Buy
68,769
+39,931
+138% +$2.79M 0.31% 106
2025
Q4 		$2.36M Buy
+28,838
New +$2.15M 0.13% 191

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cinctive Capital Management's TARS Position: Q2 2026 in Review

Cinctive Capital Management reduced its Tarsus Pharmaceuticals (TARS) stake by 33% in Q2 2026, selling an estimated $1.44M and leaving 46,182 shares worth $2.91M. The position accounts for 0.11% of the portfolio, ranked #237.

Cinctive Capital Management first reported a position in TARS in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.82M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Cinctive Capital Management held 46,182 shares of Tarsus Pharmaceuticals worth $2.91M as of Q2 2026.
  • Cinctive Capital Management sold 22,587 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • Tarsus Pharmaceuticals made up 0.11% of Cinctive Capital Management's portfolio in Q2 2026, its #237 holding.
  • Cinctive Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Cinctive Capital Management's Tarsus Pharmaceuticals position peaked at $4.82M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.